p38 alpha MAPK inhibitors (Syncom/University Medical Center Groningen)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namep38 alpha MAPK inhibitors (Syncom/University Medical Center Groningen)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSyncom Bv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSyncom BvUniversity Medical Center Groningen
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A